vs
Clipper Realty Inc.（CLPR）与MESA LABORATORIES INC（MLAB）财务数据对比。点击上方公司名可切换其他公司
MESA LABORATORIES INC的季度营收约是Clipper Realty Inc.的1.8倍（$65.1M vs $37.1M），MESA LABORATORIES INC净利率更高（5.6% vs -30.4%，领先36.0%），MESA LABORATORIES INC同比增速更快（3.6% vs -2.6%），过去两年MESA LABORATORIES INC的营收复合增速更高（5.1% vs 1.8%）
Clipper Realty Inc.旗下Clipper Equity由大卫·比斯特里瑟和山姆·莱文森牵头成立，在美国纽约与新泽西州拥有超60栋物业，合计数千套住宅单元。该企业最为人熟知的事迹是曾在2007年2月出价13亿美元收购纽约布鲁克林的斯塔雷特城住宅区，该交易曾是当时全球规模最大的房地产交易之一。
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
CLPR vs MLAB — 直观对比
营收规模更大
MLAB
是对方的1.8倍
$37.1M
营收增速更快
MLAB
高出6.2%
-2.6%
净利率更高
MLAB
高出36.0%
-30.4%
两年增速更快
MLAB
近两年复合增速
1.8%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $37.1M | $65.1M |
| 净利润 | $-11.3M | $3.6M |
| 毛利率 | -5.2% | 64.2% |
| 营业利润率 | 21.8% | 12.2% |
| 净利率 | -30.4% | 5.6% |
| 营收同比 | -2.6% | 3.6% |
| 净利润同比 | -938.6% | 316.6% |
| 每股收益（稀释后） | — | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLPRMLAB
| Q4 25 | $37.1M | $65.1M | ||
| Q3 25 | $37.7M | $60.7M | ||
| Q2 25 | $39.0M | $59.5M | ||
| Q1 25 | $39.4M | $62.1M | ||
| Q4 24 | $38.0M | $62.8M | ||
| Q3 24 | $37.6M | $57.8M | ||
| Q2 24 | $37.3M | $58.2M | ||
| Q1 24 | $35.8M | $58.9M |
净利润CLPRMLAB
| Q4 25 | $-11.3M | $3.6M | ||
| Q3 25 | $-4.6M | $2.5M | ||
| Q2 25 | $-1.4M | $4.7M | ||
| Q1 25 | $-35.1M | $-7.1M | ||
| Q4 24 | $-1.1M | $-1.7M | ||
| Q3 24 | $-1.1M | $3.4M | ||
| Q2 24 | $-1.7M | $3.4M | ||
| Q1 24 | $-2.7M | $-254.6M |
毛利率CLPRMLAB
| Q4 25 | -5.2% | 64.2% | ||
| Q3 25 | 23.6% | 61.5% | ||
| Q2 25 | 27.8% | 62.0% | ||
| Q1 25 | -34.5% | 61.8% | ||
| Q4 24 | 28.8% | 63.3% | ||
| Q3 24 | 28.6% | 61.3% | ||
| Q2 24 | 26.8% | 64.0% | ||
| Q1 24 | 25.4% | 62.1% |
营业利润率CLPRMLAB
| Q4 25 | 21.8% | 12.2% | ||
| Q3 25 | 23.6% | 7.8% | ||
| Q2 25 | 27.7% | 5.1% | ||
| Q1 25 | -59.9% | 2.4% | ||
| Q4 24 | 28.1% | 9.2% | ||
| Q3 24 | 28.6% | 6.1% | ||
| Q2 24 | 26.8% | 9.6% | ||
| Q1 24 | 25.4% | -460.6% |
净利率CLPRMLAB
| Q4 25 | -30.4% | 5.6% | ||
| Q3 25 | -12.2% | 4.1% | ||
| Q2 25 | -3.5% | 8.0% | ||
| Q1 25 | -89.1% | -11.4% | ||
| Q4 24 | -2.9% | -2.7% | ||
| Q3 24 | -2.9% | 5.9% | ||
| Q2 24 | -4.7% | 5.8% | ||
| Q1 24 | -7.5% | -432.2% |
每股收益（稀释后）CLPRMLAB
| Q4 25 | — | $0.65 | ||
| Q3 25 | — | $0.45 | ||
| Q2 25 | — | $0.85 | ||
| Q1 25 | — | $-1.30 | ||
| Q4 24 | — | $-0.31 | ||
| Q3 24 | — | $0.63 | ||
| Q2 24 | — | $0.62 | ||
| Q1 24 | — | $-47.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $30.8M | $29.0M |
| 总债务越低越好 | — | $68.4M |
| 股东权益账面价值 | $-30.7M | $186.7M |
| 总资产 | $1.2B | $434.8M |
| 负债/权益比越低杠杆越低 | — | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资CLPRMLAB
| Q4 25 | $30.8M | $29.0M | ||
| Q3 25 | $26.1M | $20.4M | ||
| Q2 25 | $32.0M | $21.3M | ||
| Q1 25 | $21.3M | $27.3M | ||
| Q4 24 | $19.9M | $27.3M | ||
| Q3 24 | $18.6M | $24.3M | ||
| Q2 24 | $20.3M | $28.5M | ||
| Q1 24 | $21.9M | $28.2M |
总债务CLPRMLAB
| Q4 25 | — | $68.4M | ||
| Q3 25 | — | $69.4M | ||
| Q2 25 | — | $70.3M | ||
| Q1 25 | $1.3B | $71.3M | ||
| Q4 24 | $1.3B | $72.2M | ||
| Q3 24 | $1.3B | $73.1M | ||
| Q2 24 | $1.2B | $74.1M | ||
| Q1 24 | $1.2B | — |
股东权益CLPRMLAB
| Q4 25 | $-30.7M | $186.7M | ||
| Q3 25 | $-25.0M | $178.5M | ||
| Q2 25 | $-21.9M | $172.5M | ||
| Q1 25 | $-20.1M | $159.8M | ||
| Q4 24 | $-5.4M | $155.2M | ||
| Q3 24 | $-3.6M | $161.5M | ||
| Q2 24 | $-1.8M | $150.7M | ||
| Q1 24 | $279.0K | $145.4M |
总资产CLPRMLAB
| Q4 25 | $1.2B | $434.8M | ||
| Q3 25 | $1.2B | $430.4M | ||
| Q2 25 | $1.2B | $435.7M | ||
| Q1 25 | $1.3B | $433.3M | ||
| Q4 24 | $1.3B | $433.3M | ||
| Q3 24 | $1.3B | $454.1M | ||
| Q2 24 | $1.3B | $440.4M | ||
| Q1 24 | $1.3B | $446.8M |
负债/权益比CLPRMLAB
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.49× | ||
| Q1 24 | 4396.73× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $22.6M | $18.8M |
| 自由现金流经营现金流 - 资本支出 | — | $18.0M |
| 自由现金流率自由现金流/营收 | — | 27.7% |
| 资本支出强度资本支出/营收 | — | 1.1% |
| 现金转化率经营现金流/净利润 | — | 5.17× |
| 过去12个月自由现金流最近4个季度 | — | $37.9M |
8季度趋势，按日历期对齐
经营现金流CLPRMLAB
| Q4 25 | $22.6M | $18.8M | ||
| Q3 25 | $1.4M | $8.2M | ||
| Q2 25 | $8.4M | $1.9M | ||
| Q1 25 | $6.7M | $12.7M | ||
| Q4 24 | $31.9M | $18.1M | ||
| Q3 24 | $6.3M | $5.3M | ||
| Q2 24 | $8.8M | $10.7M | ||
| Q1 24 | $6.3M | $12.9M |
自由现金流CLPRMLAB
| Q4 25 | — | $18.0M | ||
| Q3 25 | — | $7.1M | ||
| Q2 25 | — | $884.0K | ||
| Q1 25 | $-4.6M | $11.9M | ||
| Q4 24 | $-37.9M | $17.3M | ||
| Q3 24 | — | $3.5M | ||
| Q2 24 | — | $9.9M | ||
| Q1 24 | $-14.7M | $12.3M |
自由现金流率CLPRMLAB
| Q4 25 | — | 27.7% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | -11.7% | 19.2% | ||
| Q4 24 | -99.5% | 27.6% | ||
| Q3 24 | — | 6.0% | ||
| Q2 24 | — | 16.9% | ||
| Q1 24 | -41.1% | 21.0% |
资本支出强度CLPRMLAB
| Q4 25 | — | 1.1% | ||
| Q3 25 | — | 1.8% | ||
| Q2 25 | — | 1.7% | ||
| Q1 25 | 28.6% | 1.2% | ||
| Q4 24 | 183.3% | 1.3% | ||
| Q3 24 | — | 3.1% | ||
| Q2 24 | — | 1.5% | ||
| Q1 24 | 58.6% | 0.9% |
现金转化率CLPRMLAB
| Q4 25 | — | 5.17× | ||
| Q3 25 | — | 3.32× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.54× | ||
| Q2 24 | — | 3.17× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLPR
| Residential Segment | $30.8M | 83% |
| Commercial Real Estate | $6.2M | 17% |
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
